Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Branded formulation business continues to perform well across domestic and export markets
Subscribe To Our Newsletter & Stay Updated
_256_384.JPG)
